The African continent bears the brunt of sickle cell disease, a condition that affects millions of people worldwide. According to the World Health Organization, approximately 7.7 million people live with the disease, with the vast majority residing in sub-Saharan Africa. The condition is estimated to cause over 300,000 deaths annually, with Nigeria accounting for a significant portion of these fatalities.
The prevalence of sickle cell disease in Africa is staggering, with more than 75% of babies born with the condition worldwide being born on the continent. Every year, around 400,000 babies are born with the disease globally, with over 300,000 of these births occurring in sub-Saharan Africa. The situation is dire, with access to advanced treatment options remaining limited.
Despite the challenges, there is hope for patients living with sickle cell disease. Red blood cell exchange, a therapy that involves replacing unhealthy red cells with healthy ones, has been shown to be an effective treatment option. Clinical guidance from the American Society of Haematology recognises red blood cell exchange as a proven intervention for stroke prevention, management of severe pain crises, and life-threatening complications.
At the African Medical Centre of Excellence, clinical teams are now delivering advanced therapies, including red blood cell exchange. The centre recently completed its first red blood cell exchange using the Terumo Optia machine on a patient with sickle cell anaemia and chronic pain. The patient has remained pain-free since undergoing the exchange, illustrating the transformative potential of this therapy.
The African Medical Centre of Excellence's decision to offer red blood cell exchange is a significant step towards improving the lives of patients living with sickle cell disease. By making this therapy more accessible, the centre is providing a lifeline to families who have been told that meaningful care is only available abroad. The centre's work demonstrates that advanced, life-saving interventions are not limited to facilities abroad but are achievable within Africa. This is a crucial development, especially for Nigeria, which accounts for a significant portion of the continent's sickle cell disease burden. As the centre continues to deliver this life-saving therapy, it is essential that the government and other stakeholders provide the necessary support to ensure its sustainability.
